AltumBio Playbook
The path of a synthetic biology startup—from patenting novel organisms to navigating the FDA, EPA, and USDA—is unlike any other. We created AltumBio as a foundational legal and strategic resource to demystify these complex challenges. Our goal is to empower you to build on a compliant foundation, so you can focus on what matters most: engineering biology to solve some of the world's greatest problems. We hope this playbook serves as a trusted guide on your journey.
-
1.01 - Before You Begin: Commercial Potential and Freedom-to-Operate
1.02 - Partnering with Academia: Leveraging Your University's TTO
1.03 - Choosing Your Legal Entity: C-Corp vs. LLC for Biotech Founders
1.04 - Where to Incorporate: Strategic Decisions for Biotech Growth
1.05 - Assembling Your Core: Navigating Co-Founder Agreements
1.06 - Fair Equity Splits: Beyond the Vision to Practical Allocation
1.07 - Defining Roles and Responsibilities for Co-Founders
1.08 - Building Your Legal Dream Team: Why Biotech-Specific Counsel is Key
1.09 - Funding Your Counsel: Exploring Deferred Payment Options
1.10 - Managing Conflicts of Interest for Academic Founders
1.11 - Setting Up Employee Protections: NDAs, IP Assignment, and Non-Competes
1.12 - Protecting Your Ideas: Beyond Employees to Third-Party Vendors
1.13 - Naming Your Company: Legal and Brand Considerations
1.14 - Essential First Steps: Legal Hygiene for Biotech Startups
-
2.01 - Crafting a Robust IP Strategy: Patents, Licenses, and Trade Secrets
2.02 - IP as an Ongoing Process: Adapting Through R&D and Clinical Trials
2.03 - Foundational Patents in Synthetic Biology: The Cornerstone of Innovation
2.04 - Supplemental Patents: Protecting Your Iterative Innovations
2.05 - Navigating Patent Thickets: Proliferation of "Parts" Patents
2.06 - Open vs. Proprietary Innovation: A Symbiotic Relationship in SynBio
2.07 - Case Study: The Complexities of CRISPR/Cas9 Patent Disputes
2.08 - CRISPR Patent Ownership: CVC, Broad, and the Global Landscape
2.09 - "First to File" vs. "First to Invent": Understanding Patent Priority
2.10 - Protecting AI-Generated Inventions: Navigating a New IP Frontier
2.11 - Data Privacy and Ownership in Biological AI Models
2.12 - Ensuring Data Lineage and Output Guardrails for Bio-AI
2.13 - Licensing IP from Academia: Exclusive vs. Non-Exclusive Rights
2.14 - Trade Secrets: When Confidentiality is Your Strongest IP
-
3.01 - The Biotech Funding Landscape: From Pre-Seed to IPO
3.02 - Why Biotech Series A Rounds Are Different (and Bigger)
3.03 - Attracting Venture Capital: Biotech's Primary Funding Source
3.04 - Beyond Equity: Leveraging Non-Dilutive Funding and Government Grants
3.05 - Securing Federal Grants: SBIR/STTR and Other Programs
3.06 - Crafting a Winning Biotech Pitch Deck
3.07 - Tailoring Your Message: Pitching to Diverse Biotech Investors
3.08 - Navigating Due Diligence: Transparency and Risk Mitigation
3.09 - Forecasting Your Financial Needs and Expenditures
3.10 - Planning Your Exit Strategy: Milestones and Investor Expectations
3.11 - Biopharma's Funding Dominance: Attracting Investment in Drug Development
3.12 - AI-Driven Drug Discovery: Showcasing Your AI Capabilities to Investors
3.13 - Mega-Rounds in Biotech: Scaling for Significant Investment
3.14 - Cell and Gene Therapy: A Funding Hotspot and Its Demands
3.15 - Scalable Manufacturing: A Key for Gene Therapy Investment
3.16 - International Funding Hotspots: Opportunities in Asia-Pacific
3.17 - Financial Sustainability: Building Resilience in a High-Risk Industry
3.18 - Biotech Unicorns: The Path to Billion-Dollar Valuations
-
4.01 - The Patchwork Problem: Fragmented Regulation in Synthetic Biology
4.02 - Health and Safety Compliance: Contained Use and Risk Assessment
4.03 - Precision Breeding Laws: Navigating UK Genetic Technology Act
4.04 - Labeling Controversy: Consumer Protection in Gene-Edited Products
4.05 - National Security and Investment: Mandatory Notifications for SynBio M&A
4.06 - Counter-Terrorism: Preventing Misuse of Pathogens and Toxins
4.07 - Drug Development Regulations: Human Medicines and SynBio
4.08 - Environmental Impact: Monitoring SynBio Products in the Wild
4.09 - Liability and Insurance: De-Risking Your SynBio Product Launch
4.10 - Biosafety and Biosecurity: Core Challenges for SynBio Founders
4.11 - Dual-Use Dilemmas: Balancing Innovation and Responsible Development
4.12 - Governance Models: Hard Law, Soft Law, and Self-Regulation
4.13 - The Human Factor in Biosafety: Training and Culture of Safety
4.14 - Securing Your Biotech Facility: Beyond Basic Access Control
4.15 - International Collaboration: Addressing Global Biosecurity Gaps
4.16 - Integrating Biosecurity into Your Business Model
4.17 - Ethical AI in Biology: Data Privacy, Ownership, and Bias
4.18 - The Role of Public Engagement: Building Trust in Synthetic Biology
-
5.01 - From Lab Bench to Commercial Scale: The De-Risking Journey
5.02 - The Biology Foundry Model: Infrastructure for Engineering at Scale
5.03 - Automation in the Lab: Precision, Speed, and Cost Efficiency
5.04 - Designing for Scalability: Robust Scale-Down Models
5.05 - Techno-Economic Analysis (TEA): The "Math is Free" Principle
5.06 - Life Cycle Analysis (LCA): Assessing Environmental Footprint from Day One
5.07 - Overcoming Scaling Pain Points: Fluid Dynamics and Mass Flow
5.08 - Hybrid Approaches: Integrating Biology with Chemical Engineering Processes
5.09 - Building the "Bio Belt": Regional Biomanufacturing Hubs
5.10 - Workforce for Scale: The Diverse Talent Your SynBio Company Needs
5.11 - Supply Chain for SynBio Products: From Raw Materials to Delivery
5.12 - Automation in Biomanufacturing: Hardware and Software Solutions
5.13 - Digital Tracking and Traceability: Ensuring Chain of Identity and Custody
5.14 - Partnering for Production: CDMOs and Biomanufacturing Strategy
5.15 - Optimizing Strains and Enzymes for Industrial Bioproduction
5.16 - Circular Economy Principles: Designing for Biological Resource Cycling
5.17 - Strategic Partnerships for Climate Impact: Industry Collaboration
-
6.01 - AI as the Engine of Biotech's Future: Accelerating Innovation
6.02 - The Healthcare "Leapfrog" Opportunity with AI
6.03 - Healthcare as a Logistics and Consumer Engagement Problem: AI Solutions
6.04 - AI Models for Biological Engineering: LLMs and Beyond
6.05 - Foundation Models and Fine-Tuned Applications in Bio-AI
6.06 - The Ginkgo-Google Cloud Partnership: A Model for Bio-Tech Collaboration
6.07 - Scaling Clinical Judgment with AI: Addressing Healthcare Workforce Shortages
6.08 - Regulatory Frameworks for AI in Healthcare: FDA's Role
6.09 - AI-Enhanced Enzyme Engineering: Speeding Up Discovery and Optimization
6.10 - AI in Biosecurity: Early Warning Systems for Global Health Threats
6.11 - Traveler-Based Genomic Surveillance and Wastewater Monitoring
6.12 - The "Ground Truth Factory": Ensuring AI Reliability in Biotech
6.13 - Consumer Health Tech: The Next Trillion-Dollar Opportunity
6.14 - Wearable Devices and Personalized Health: The Future of Preventative Care
6.15 - Synthetic Biology for Climate Action: From Genes to Gigatons
6.16 - Engineering Biological Systems for Carbon Capture and Removal
6.17 - The Next Generation of Gene Therapies and Their Delivery Challenges
6.18 - Novel Genome Editing Tools: Mining Metagenomics for New Capabilities
6.19 - The Future of Food: SynBio for Sustainable Agriculture and Alternative Proteins